{"id":"W2104721463","doi":"10.1158/1078-0432.ccr-07-0382","title":"Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Sorafenib; Medicine; Erlotinib; Pharmacokinetics; Adverse effect; Rash; Pharmacology; Internal medicine; Oncology; Hepatocellular carcinoma; Epidermal growth factor receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001118273,0.001626398,0.002272914,0.0003654665,0.000393406,0.0006790452,0.0005867612,0.000708422,0.002707281],"category_scores_gemma":[0.0006826313,0.000473065,0.0008966278,0.0003585643,0.0007204078,0.0005917947,0.0003383513,0.002211408,0.0006249871],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008046236,"about_ca_system_score_gemma":0.001585016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005678067,"about_ca_topic_score_gemma":0.00151256,"domain_scores_codex":[0.9995536,0.0001781735,0.0000299852,0.00007749516,0.00006579902,0.00009485212],"domain_scores_gemma":[0.9994707,0.00007259025,0.0001072233,0.00003122166,0.00003213343,0.000286128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7803534,0.06667653,0.01115126,0.0008160261,0.001395152,0.0005431196,0.0003240628,0.003764477,0.04574423,0.0002366421,0.003055107,0.08594],"study_design_scores_gemma":[0.4754819,0.5045904,0.01198953,0.00002836854,0.0003517735,0.0003344887,0.00004069628,0.00177249,0.003499436,0.00009072557,0.001800327,0.00001993524],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950089,0.001243658,0.000406823,0.0002382542,0.00008727715,0.001584646,0.0003538821,0.00004584665,0.001030678],"genre_scores_gemma":[0.9941964,0.0006963581,0.0009896456,0.000288,0.0001414242,0.001428435,0.0010653,0.000008597026,0.001185803],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002707281,"threshold_uncertainty_score":0.009056747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1143076126728617,"score_gpt":0.5290445278227675,"score_spread":0.4147369151499057,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}